Log in

Phathom Pharmaceuticals News Headlines (NASDAQ:PHAT)

$28.42
+3.36 (+13.41 %)
(As of 04/3/2020 03:23 AM ET)
Today's Range
$24.71
Now: $28.42
$30.35
50-Day Range
$24.65
MA: $33.10
$42.83
52-Week Range
$18.51
Now: $28.42
$47.84
Volume48,388 shs
Average Volume82,141 shs
Market Capitalization$823.19 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Headlines

Phathom Pharmaceuticals (NASDAQ PHAT) News Headlines

Source:
DateHeadline
Phathom Pharmaceuticals (NASDAQ:PHAT) Major Shareholder Ra Capital Management, L.P. Buys 30,600 SharesPhathom Pharmaceuticals (NASDAQ:PHAT) Major Shareholder Ra Capital Management, L.P. Buys 30,600 Shares
www.americanbankingnews.com - March 31 at 7:16 PM
Phathom Pharmaceuticals (NASDAQ:PHAT) Major Shareholder Acquires $738,000.00 in StockPhathom Pharmaceuticals (NASDAQ:PHAT) Major Shareholder Acquires $738,000.00 in Stock
www.americanbankingnews.com - March 31 at 7:16 PM
Comparing Phathom Pharmaceuticals (PHAT) and Its PeersComparing Phathom Pharmaceuticals (PHAT) and Its Peers
www.americanbankingnews.com - March 31 at 3:34 PM
Phathom Pharmaceuticals (NASDAQ:PHAT) Posts  Earnings Results, Misses Estimates By $2.72 EPSPhathom Pharmaceuticals (NASDAQ:PHAT) Posts Earnings Results, Misses Estimates By $2.72 EPS
www.americanbankingnews.com - March 20 at 8:51 AM
BRIEF-Phathom Pharma Pauses New Patient Randomization In Trials Due To CoronavirusBRIEF-Phathom Pharma Pauses New Patient Randomization In Trials Due To Coronavirus
www.reuters.com - March 20 at 12:14 AM
PHAT.OQ - Phathom Pharmaceuticals Inc Profile | ReutersPHAT.OQ - Phathom Pharmaceuticals Inc Profile | Reuters
www.reuters.com - March 19 at 1:05 PM
Phathom Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Clinical Trial Status and Business UpdatesPhathom Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Clinical Trial Status and Business Updates
finance.yahoo.com - March 19 at 9:12 AM
Phathom Pharmaceuticals reports FY resultsPhathom Pharmaceuticals reports FY results
seekingalpha.com - March 19 at 8:44 AM
ReAlta Life Sciences Strengthens Board of Directors with Appointments of Industry Leaders Dr. Deborah Geraghty and Dr. Azmi NabulsiReAlta Life Sciences Strengthens Board of Directors with Appointments of Industry Leaders Dr. Deborah Geraghty and Dr. Azmi Nabulsi
www.businesswire.com - March 10 at 2:11 PM
Phathom Pharmaceuticals to Present at 40th Annual Cowen and Company Health Care Conference on March 2, 2020Phathom Pharmaceuticals to Present at 40th Annual Cowen and Company Health Care Conference on March 2, 2020
www.benzinga.com - February 25 at 4:50 PM
Phathom Pharmaceuticals: A Clinical-Stage Company With A De-Risked Pipeline For 2020Phathom Pharmaceuticals: A Clinical-Stage Company With A De-Risked Pipeline For 2020
seekingalpha.com - February 18 at 10:57 PM
Frazier Healthcare Partners Closes Oversubscribed $617 Million Life Sciences FundFrazier Healthcare Partners Closes Oversubscribed $617 Million Life Sciences Fund
finance.yahoo.com - January 16 at 12:14 PM
Phathom Pharmaceuticals Appoints Martin J. Gilligan as Chief Commercial OfficerPhathom Pharmaceuticals Appoints Martin J. Gilligan as Chief Commercial Officer
finance.yahoo.com - January 6 at 8:32 AM
Phathom Pharmaceuticals Announces Initiation of Pivotal Phase 3 Clinical Trial for Vonoprazan in Helicobacter Pylori (H. pylori) InfectionPhathom Pharmaceuticals Announces Initiation of Pivotal Phase 3 Clinical Trial for Vonoprazan in Helicobacter Pylori (H. pylori) Infection
finance.yahoo.com - December 23 at 8:59 AM
Phathom Pharma launches late-stage study of vonoprazan in erosive esophagitisPhathom Pharma launches late-stage study of vonoprazan in erosive esophagitis
seekingalpha.com - December 3 at 7:34 AM
Phathom Pharmaceuticals Expands Leadership Team and Announces Board TransitionPhathom Pharmaceuticals Expands Leadership Team and Announces Board Transition
finance.yahoo.com - December 2 at 8:53 AM
Phathom Pharmaceuticals Announces Initiation of Pivotal Phase 3 Clinical Trial for Vonoprazan in Erosive EsophagitisPhathom Pharmaceuticals Announces Initiation of Pivotal Phase 3 Clinical Trial for Vonoprazan in Erosive Esophagitis
finance.yahoo.com - December 2 at 8:53 AM
Phathom Pharmaceuticals to Present at Evercore ISI 2019 HealthCONx ConferencePhathom Pharmaceuticals to Present at Evercore ISI 2019 HealthCONx Conference
finance.yahoo.com - November 26 at 8:51 AM
Phathom Pharmaceuticals EPS of -$9.30Phathom Pharmaceuticals EPS of -$9.30
seekingalpha.com - November 25 at 9:16 AM
Phathom Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate UpdatePhathom Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update
finance.yahoo.com - November 25 at 9:16 AM
Phathom Pharmaceuticals to Present at Jefferies 2019 London Healthcare ConferencePhathom Pharmaceuticals to Present at Jefferies 2019 London Healthcare Conference
finance.yahoo.com - November 13 at 7:56 PM
Phathom Pharmaceuticals Rises Almost 30% After $182 MillionPhathom Pharmaceuticals Rises Almost 30% After $182 Million
finance.yahoo.com - November 1 at 4:40 PM
Phathom Pharmaceuticals Rises Almost 30% After $182 MillionPhathom Pharmaceuticals Rises Almost 30% After $182 Million
finance.yahoo.com - November 1 at 4:40 PM
Phathom Pharmaceuticals Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesPhathom Pharmaceuticals Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
finance.yahoo.com - November 1 at 4:40 PM
Phathom Pharmaceuticals Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesPhathom Pharmaceuticals Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
finance.yahoo.com - November 1 at 4:40 PM
This page was last updated on 4/3/2020 by MarketBeat.com Staff

Featured Article: What is net income?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel